Evolent Health, Inc (NYSE:EVH – Get Free Report) has received an average recommendation of “Buy” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.0714.
Several analysts recently weighed in on EVH shares. Piper Sandler upped their price target on Evolent Health from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. JMP Securities restated a “market outperform” rating and issued a $13.00 price target on shares of Evolent Health in a research note on Friday, June 20th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a research note on Tuesday, May 13th. Finally, Truist Financial increased their target price on Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, July 17th.
Read Our Latest Stock Report on Evolent Health
Hedge Funds Weigh In On Evolent Health
Evolent Health Stock Performance
Evolent Health stock opened at $9.66 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $1.13 billion, a P/E ratio of -6.00 and a beta of 0.73. The stock’s 50 day moving average is $10.01 and its 200 day moving average is $9.51. Evolent Health has a twelve month low of $7.06 and a twelve month high of $31.80.
Evolent Health (NYSE:EVH – Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The company had revenue of $444.33 million during the quarter, compared to analysts’ expectations of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business’s quarterly revenue was down 31.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. On average, equities research analysts predict that Evolent Health will post 0.08 earnings per share for the current fiscal year.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Featured Stories
- Five stocks we like better than Evolent Health
- Using the MarketBeat Dividend Tax Calculator
- 3 Big Dividend Hikes Hit the Market—1 Just Doubled Its Payout
- What Are Dividends? Buy the Best Dividend Stocks
- What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave Stock
- How to Choose Top Rated Stocks
- 3 Undervalued Stocks Poised to Shine in the Next Market Rally
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.